<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04801160</url>
  </required_header>
  <id_info>
    <org_study_id>REMS-TAI-HC-2021</org_study_id>
    <nct_id>NCT04801160</nct_id>
  </id_info>
  <brief_title>REMS Combined With TAI for Unresectable HC</brief_title>
  <official_title>Radiation-Emitting Metallic Stents (REMS) Combined With Trans-Arterial Infusion (TAI) Versus Uncovered Self-Expandable Metallic Stent (SEMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongda Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongda Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized controlled study is to evaluate the efficacy and safety of the&#xD;
      Radiation-Emitting Metallic Stents (REMS) combined with Trans-Arterial Infusion (TAI) for&#xD;
      unresectable hilar cholangiocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentric, open-labal, randomized controlled trial which aims to evaluate the&#xD;
      efficacy and safety of Radiation-Emitting Metallic Stents (REMS) combined with Trans-Arterial&#xD;
      Infusion (TAI) versus Uncovered Self-Expandable Metallic Stent (SEMS) Combined With&#xD;
      Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma. The primary&#xD;
      hypotheses are that Radiation-Emitting Metallic Stents (REMS) combined with Trans-Arterial&#xD;
      Infusion (TAI) is superior to Uncovered Self-Expandable Metallic Stent (SEMS) Combined With&#xD;
      Trans-Arterial Infusion (TAI) with respect to Over survival(OS). The primary endpoint is&#xD;
      overall survival. The secondary endpoints include quality of life, progression free survival,&#xD;
      relief of jaundice, patency, and adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Participants will be followed till die or lost to follow-up, an expected average of a year.</time_frame>
    <description>Time from treatment to the day when the patients died or lost to the follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>QoL would be estimated at baseline, at 4 weeks, and at 12 weeks.</time_frame>
    <description>QoL would be estimated by using European for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Participants will be followed till progression appeared or die or lost to follow-up, an expected average of a year.</time_frame>
    <description>Time from stenting to the day when progression appeared or the patients died from any cause or lost to the follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency</measure>
    <time_frame>Participants will be followed till die or lost to follow-up, an expected average of a year.</time_frame>
    <description>Time from stent placement to the day when re-stenosis of the stent occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Participants will be followed till die or lost to follow-up, an expected average of a year.</time_frame>
    <description>Including side effect/complication, radioactive safety. Complications would be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE 4.03).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relief of jaundice</measure>
    <time_frame>Relief of jaundice was evaluated within 1 week after stent implantation.</time_frame>
    <description>Relief of jaundice was defined as reduction of more than 20% total bilirubin within 1 week after stent implantation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Unresectable Hilar Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>REMS+TAI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation-Emitting Metallic Stents (REMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEMS+TAI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Uncovered Self-Expandable Metallic Stent (SEMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>REMS+TAI</intervention_name>
    <description>Radiation-Emitting Metallic Stents (REMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma</description>
    <arm_group_label>REMS+TAI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SEMS+TAI</intervention_name>
    <description>Uncovered Self-Expandable Metallic Stent (SEMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma</description>
    <arm_group_label>SEMS+TAI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or pathological diagnosis of cholangiocarcinoma&#xD;
&#xD;
          -  With symptoms such as jaundice related to biliary obstruction&#xD;
&#xD;
          -  Biliary obstruction of Bismuth-Correlate Classification Type III or IV&#xD;
&#xD;
          -  Unresectable disease confirmed by multidisciplinary team&#xD;
&#xD;
          -  Maximum diameter of lesion ≤3 cm&#xD;
&#xD;
          -  Liver function of Child-Pugh A or B&#xD;
&#xD;
          -  18-75 years old&#xD;
&#xD;
          -  With an expected survival time ≥ 3 months&#xD;
&#xD;
          -  With an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2&#xD;
&#xD;
          -  Meet the following laboratory test parameters: hematologic function (absolute&#xD;
             neutrophil count ≥ 1.0×10⁹/L; platelet count ≥ 50×10⁹/L; hemoglobin ≥ 90 g/L; INR &lt;&#xD;
             1.7 or prolonged prothrombin time not more than 4 seconds); liver function (ALT/AST&#xD;
             not more than 5 times the upper limit of normal; albumin ≥ 28 g/L); renal function&#xD;
             (serum creatinine not more than 1.5 times the upper limit of normal)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of distant metastases&#xD;
&#xD;
          -  With another malignancy type other than cholangiocarcinoma&#xD;
&#xD;
          -  Previous history of biliary stent placement&#xD;
&#xD;
          -  Moderate to severe ascites (ascites up to Child-Pugh score of 3)&#xD;
&#xD;
          -  Biliary perforation&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 4 weeks prior to enrollment&#xD;
&#xD;
          -  Unstable angina, myocardial infarction, coronary artery bypass graft, congestive heart&#xD;
             failure, cerebrovascular accident (including transient ischemic attack, pulmonary&#xD;
             embolism) within 3 months before enrollment&#xD;
&#xD;
          -  Persistent arrhythmia (CTCAE criteria grade 2 and above), atrial fibrillation of any&#xD;
             degree, prolonged Qtc interval (more than 450 ms in men and more than 470 ms in women)&#xD;
&#xD;
          -  Refractory hypertension (blood pressure above 150/100 mmHg even after optimal drug&#xD;
             therapy&#xD;
&#xD;
          -  Concomitant receipt of other anti-tumor drugs&#xD;
&#xD;
          -  Concomitant human immunodeficiency virus (HIV) infection or acquired immunodeficiency&#xD;
             syndrome&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Concomitant acute or chronic mental disorders (including mental disorders affecting&#xD;
             subject enrollment, therapeutic intervention, and follow-up)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-He Guo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongda Hospital Southeast University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Lu, MD</last_name>
    <phone>+86 15850654644</phone>
    <email>lujian43307131@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongda Hospital,Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qi Chen, MD</last_name>
      <phone>+86 15651925693</phone>
      <email>qcyzzhcq@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhongda Hospital</investigator_affiliation>
    <investigator_full_name>Jin-He Guo</investigator_full_name>
    <investigator_title>Deputy Director, Center of Interventional Radiology &amp; Vascular Surgery</investigator_title>
  </responsible_party>
  <keyword>Unresectable hilar cholangiocarcinoma</keyword>
  <keyword>Irradiation stent</keyword>
  <keyword>Conventional stent</keyword>
  <keyword>Trans-arterial infusion</keyword>
  <keyword>Bile duct</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Klatskin Tumor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

